Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer
NCT ID: NCT03435536
Last Updated: 2025-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
35 participants
INTERVENTIONAL
2018-02-26
2022-06-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma
NCT06478056
PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT
NCT05802485
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
NCT05356039
INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors
NCT04436679
Covid-19 Pandemic and Pancreatic Surgery in Italy
NCT04380766
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Circulating tumor DNA
circulating tumor DNA rate at various times of pancreatic cancer resection
Blood samples
Blood samples will be taken to analyze the circulating tumor DNA rate by NGS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood samples
Blood samples will be taken to analyze the circulating tumor DNA rate by NGS
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient aged over 18 years old
* Patient having given his written consent
* Patient with social insurance coverage
Exclusion Criteria
* Patient for whom the surgery was not realized (exploratory laparotomy)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Toulouse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emmanuel CUELLAR, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Toulouse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Maulat C, Canivet C, Cabarrou B, Pradines A, Selves J, Casanova A, Doussine A, Hanoun N, Cuellar E, Boulard P, Carrere N, Buscail L, Bournet B, Muscari F, Cordelier P. Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients. Sci Rep. 2024 Nov 8;14(1):27296. doi: 10.1038/s41598-024-76903-y.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC31/17/0327
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.